Humanized Antibody

Humanized Antibody

Humanized antibodies are antibodies from non-human species whose protein sequences have been modified to increase their similarity to antibody variants produced naturally in humans. The process of "humanization" is usually applied to monoclonal antibodies developed for administration to humans (for example, antibodies developed as anti-cancer drugs). Humanization can be necessary when the process of developing a specific antibody involves generation in a non-human immune system (such as that in mice). The protein sequences of antibodies produced in this way are partially distinct from homologous antibodies occurring naturally in humans, and are therefore potentially immunogenic when administered to human patients (see also Human anti-mouse antibody). Not all monoclonal antibodies designed for human administration need be humanized since many therapies are short-term interventions (see List of monoclonal antibodies to get an overview of the various types of antibodies developed for therapeutic administration in humans). The International Nonproprietary Names of humanized antibodies end in -zumab, as in omalizumab (see Nomenclature of monoclonal antibodies).

Humanized antibodies are distinct from chimeric antibodies. The latter also have their protein sequences made more similar to human antibodies, but carry a larger stretch of non-human protein.

Read more about Humanized Antibody:  Use of Recombinant DNA in Humanization Process, Distinction From "chimeric Antibody", Humanizing Via A Chimeric Intermediate, Humanization By Insertion of Relevant CDRs Into Human Antibody "scaffold", Antibodies For Human Therapy Derived Without Using Mice

Other articles related to "antibody, humanized, humanized antibody":

Monoclonal Antibody Therapy - FDA Approved Therapeutic Antibodies
... The first FDA-approved therapeutic monoclonal antibody was a murine IgG2a CD3 specific transplant rejection drug, OKT3 (also called muromonab), in 1986 ... Example FDA approved therapeutic monoclonal antibodies Antibody Brand name Company Approval date Type Target Indication (Targeted disease) Abciximab ReoPro Eli Lilly 1994 chimeric inhibition ... Natalizumab Tysabri Biogen Idec/Élan 2006 humanized alpha-4 (α4) integrin, Multiple sclerosis and Crohn's disease Ofatumumab Arzerra 2009 Human CD20 Chronic lymphocytic ...
Cancer Immunotherapy - Monoclonal Antibody Therapy
... The advent of monoclonal antibody technology has made it possible to raise antibodies against specific antigens such as the unusual antigens that are presented on the surfaces of tumors ... Cancer immunotherapyMonoclonal antibodies Antibody Brand name Approval date Type Target Approved treatment(s) Alemtuzumab Campath 2001 humanized CD52 Chronic lymphocytic leukemia Bevacizumab ...
Tanox - Antibody Therapeutics
... Among the humanized antibody drugs Tanox developed by itself or with corporate partners Omalizumab, trade name Xolair TNX-901, also referred to as ... been obtained from two Phase I and one Phase IIa clinical trails on a humanized antibody, 47H4 (also referred to as MEMP1972A, or quilizumab) ... These clinical trial results have shown that the anti-M1’ antibody is safe and can block the synthesis of allergen-specific IgE and associated allergic response upon ...
List Of Monoclonal Antibodies
... The abbreviations in the column Type are as follows mab whole monoclonal antibody Fab fragment, antigen-binding (one arm) F(ab')2 fragment, antigen-binding, including hinge region (both arms) Fab' fragment ... prostate and breast cancer Afelimomab F(ab')2 mouse TNF-α sepsis Afutuzumab mab humanized CD20 lymphoma Alacizumab pegol F(ab')2 humanized VEGFR2 cancer ALD518 ? humanized IL-6 rheumatoid arthritis Alemtuzumab ... Benralizumab mab humanized CD125 asthma Bertilimumab mab human CCL11 (eotaxin-1) severe allergic disorders Besilesomab Scintimun mab mouse CEA-related antigen inflammatory ...